AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6121138 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 50
Study 6121138 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 50
Study 30874775 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (PA) measured by accelerometry
Number of subjects: 5861
Study 29210507 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid syrup (IFAS) administered twice weekly for 1 month
Number of subjects: 100
Study 29210507 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MNPs) for 1 month
Number of subjects: 100
Study 26875894 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation combined high frequency electric knife therapy
Number of subjects: 56
Study 26875894 — intervention group
Group type: COMPARATOR
Intervention: High frequency electric band ligation electroexcision
Number of subjects: 56
Study 23709097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 3210
Study 23709097 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 3210
Study 23709097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3210
Study 21872537 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized interventions developed using the Treatment Routes for Exploring Agitation decision tree protocol
Number of subjects: 89
Study 21872537 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful interventions presented after the feasibility period
Number of subjects: 89
Study 19421022 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ocular lubricant
Number of subjects: 110
Study 19421022 — intervention group
Group type: COMPARATOR
Intervention: Marketed ocular lubricant
Number of subjects: 110
Study 17341510 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest Brink scale scores (n=75)
Number of subjects: 317
Study 17341510 — intervention group
Group type: COMPARATOR
Intervention: Lowest Brink scale scores (n=56)
Number of subjects: 317
Study 15965635 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 16) for 2 weeks in addition to medical treatment
Number of subjects: 30
Study 15965635 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14) continued medical treatment and/or daily exercises
Number of subjects: 30
Study 15965635 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 16)
Number of subjects: 30
Study 11896092 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x DOC (100 mg/m(2))
Number of subjects: 162
Study 11896092 — intervention group
Group type: COMPARATOR
Intervention: 4 x CVAP
Number of subjects: 162
Study 11896092 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x DOC (for nonresponders)
Number of subjects: 162
Study 10207925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) and furosemide (FUR) treatment
Number of subjects: 16
Study 10207925 — intervention group
Group type: COMPARATOR
Intervention: Serial lumbar puncture (LP)
Number of subjects: 16
Study 8568782 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 0
Study 8568782 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 0
Study 8568782 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study 2222823 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20
Study 2222823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 104570 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iodamide 24%
Number of subjects: 283
Study 104570 — intervention group
Group type: COMPARATOR
Intervention: Meglumine diatrizoate 30%
Number of subjects: 283
Study 30447156 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 30
Study 30447156 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 30
Study 30447156 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 30
Study 30447156 — intervention group
Group type: EXPERIMENTAL
Intervention: chloroquine
Number of subjects: 30
Study 30447156 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem
Number of subjects: 30
Study 29110972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg added to insulin glargine
Number of subjects: 0
Study 29110972 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to insulin glargine
Number of subjects: 0
Study 27567670 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified (new technique) stitch
Number of subjects: 160
Study 27567670 — intervention group
Group type: COMPARATOR
Intervention: Classic technique (B-Lynch suture)
Number of subjects: 160
Study 25143061 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention for 3 months after CHT
Number of subjects: 169
Study 22020607 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of 10 mg of etanercept and 2.0 mL of lidocaine
Number of subjects: 80
Study 22020607 — intervention group
Group type: COMPARATOR
Intervention: Epidural administration of 3.3 mg of dexamethasone and 2.0 mL of lidocaine
Number of subjects: 80
Study 19328352 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy with silicone intubation
Number of subjects: 38
Study 19328352 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy without silicone intubation
Number of subjects: 38
Study 17761319 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extracorporeal shockwave therapy (0.25 mJ/mm(2))
Number of subjects: 40
Study 17761319 — intervention group
Group type: COMPARATOR
Intervention: Sham shockwave therapy
Number of subjects: 40
Study 15066896 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-meds and QI-therapy
Number of subjects: 1356
Study 15066896 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-therapy
Number of subjects: 1356
Study 15066896 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study 12098059 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic wound wick (povidone-iodine soaked ribbon gauze)
Number of subjects: 174
Study 12098059 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular wound closure
Number of subjects: 174
Study 10436094 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 220
Study 10436094 — intervention group
Group type: COMPARATOR
Intervention: General Wards (GW)
Number of subjects: 220
Study 8664455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (7 micrograms/kg/min)
Number of subjects: 2
Study 8664455 — intervention group
Group type: COMPARATOR
Intervention: Insulin (1.5 U/kg/h)
Number of subjects: 2
Study 1972963 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflowerseed oil (60 ml/day)
Number of subjects: 44
Study 1972963 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil (60 ml/day)
Number of subjects: 44
Study 1972963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (60 ml/day)
Number of subjects: 44
Study 369924 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 800 mg/day
Number of subjects: 24
Study 369924 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 80 mg/day
Number of subjects: 24
Study 30852257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 64
Study 30852257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27461773 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus paclitaxel plus carboplatin/cisplatin
Number of subjects: 109
Study 27461773 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel plus carboplatin/cisplatin
Number of subjects: 109
Study 27003895 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of FE 999049 at doses of 37.5, 75, 150, 225, or 450 IU
Number of subjects: 27
Study 24480729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HOME Plus program)
Number of subjects: 0
Study 24480729 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention-only)
Number of subjects: 0
Study 22958287 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 48
Study 22958287 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 48
Study 19278583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin and thymosin alpha1, 200 kU IV twice a day for 4 days, then 100 kU for 6 days; thymosin alpha1, 1.6 mg subcutaneous twice a day for 4 days, then 1.6 mg per day for 6 days.
Number of subjects: 242
Study 19278583 — intervention group
Group type: COMPARATOR
Intervention: Control group received conventional treatment according to Surviving Sepsis Campaign (SSC) 2004.
Number of subjects: 242
Study 17404794 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-T3 ablation
Number of subjects: 25
Study 17404794 — intervention group
Group type: COMPARATOR
Intervention: T2 ablation
Number of subjects: 25
Study 15637978 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel integrated power toothbrush and toothpaste system
Number of subjects: 0
Study 15637978 — intervention group
Group type: COMPARATOR
Intervention: Nonintegrated power toothbrush and regular toothpaste
Number of subjects: 0
Study 11480461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine in 10% glucose with 0.025% phenylephrine (group P)
Number of subjects: 64
Study 11480461 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tetracaine in 10% glucose (group C)
Number of subjects: 64
Study 9683957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1%
Number of subjects: 30
Study 9683957 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DCG) 2%
Number of subjects: 30
Study 9683957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1%
Number of subjects: 30
Study 9683957 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 7935897 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (received a list with actual medication and recommendations by the pharmacist)
Number of subjects: 196
Study 7935897 — intervention group
Group type: COMPARATOR
Intervention: Group A (control group, sent prescriptions as before)
Number of subjects: 196
Study 7935897 — intervention group
Group type: COMPARATOR
Intervention: Group B (received a list with medication used by their patients)
Number of subjects: 196
Study 7935897 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 196
Study 3363024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 131
Study 3363024 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 131
Study 3363024 — intervention group
Group type: COMPARATOR
Intervention: Lactate-induced panic attacks in controls
Number of subjects: 131
Study 3363024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-induced panic attacks in patients
Number of subjects: 131
Study 29246950 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 813
Study 29246950 — intervention group
Group type: COMPARATOR
Intervention: Exenatide ER 2.0 mg
Number of subjects: 813
Study 27481188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE) with bicarbonate local infusion
Number of subjects: 77
Study 27481188 — intervention group
Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE) without bicarbonate local infusion
Number of subjects: 77
Study 24708031 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (18 μg once daily)
Number of subjects: 54
Study 24708031 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol (150 μg once daily)
Number of subjects: 54
Study 24708031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium plus Indacaterol (combined therapy)
Number of subjects: 54
Study 23000116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (annual prostate-specific antigen for 6 years and digital rectal exam for 4 years)
Number of subjects: 76693
Study 23000116 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 76693
Study 23000116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (within the intervention arm)
Number of subjects: 76693
Study 23000116 — intervention group
Group type: EXPERIMENTAL
Intervention: All PLCO cases
Number of subjects: 76693
Study 23000116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason 5‐7 cases
Number of subjects: 76693
Study 23000116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason 8‐10 cases
Number of subjects: 76693
Study 20518086 — intervention group
Group type: EXPERIMENTAL
Intervention: Viusid (3 sachets daily)
Number of subjects: 60
Study 20518086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19023825 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief tobacco cessation intervention with fax referral to Quitline
Number of subjects: 0
Study 19023825 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 0
Study 15739653 — intervention group
Group type: EXPERIMENTAL
Intervention: UlcerCare leg wrap (treatment)
Number of subjects: 26
Study 15739653 — intervention group
Group type: COMPARATOR
Intervention: Sham non‐magnetic device (control)
Number of subjects: 26
Study 12449022 — intervention group
Group type: EXPERIMENTAL
Intervention: Coltosol
Number of subjects: 100
Study 12449022 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 100
Study 12449022 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotch Bond
Number of subjects: 100
Study 12449022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no barrier material)
Number of subjects: 100
Study 12449022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidrion R
Number of subjects: 100
Study 10614952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg
Number of subjects: 12
Study 10614952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 400 mg
Number of subjects: 12
Study 10614952 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg
Number of subjects: 12
Study 8602779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 8
Study 8602779 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (control)
Number of subjects: 8
Study 8458192 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 16
Study 8458192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8458192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 16
Study 3529803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon) used during anterior capsulotomy and lens implantation, aspirated at the end of surgery (Group I)
Number of subjects: 69
Study 3529803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon) + 500 mg acetazolamide at the end of surgery (Group II)
Number of subjects: 69
Study 3529803 — intervention group
Group type: COMPARATOR
Intervention: BSS and/or air used instead of Healon during surgery (Group III)
Number of subjects: 69
Study 31177885 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal (excitatory) tDCS
Number of subjects: 30
Study 31177885 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 28552274 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic gelatin sponge
Number of subjects: 76
Study 28552274 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl acetate
Number of subjects: 76
Study 28552274 — intervention group
Group type: COMPARATOR
Intervention: Both packs
Number of subjects: 76
Study 28552274 — intervention group
Group type: COMPARATOR
Intervention: Cost of the pack
Number of subjects: 76
Study 28552274 — intervention group
Group type: COMPARATOR
Intervention: Wound healing
Number of subjects: 76
Study 27231096 — intervention group
Group type: EXPERIMENTAL
Intervention: Rested condition
Number of subjects: 16
Study 27231096 — intervention group
Group type: COMPARATOR
Intervention: Sleep-deprived condition
Number of subjects: 16
Study 25744780 — intervention group
Group type: EXPERIMENTAL
Intervention: About Eating (AE) program
Number of subjects: 288
Study 24505906 — intervention group
Group type: EXPERIMENTAL
Intervention: Local periprostatic anesthesia with 10 ml of lidocaine
Number of subjects: 100
Study 24505906 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 100
Study 21781338 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders (ComRem)
Number of subjects: 739
Study 21781338 — intervention group
Group type: COMPARATOR
Intervention: Postal reminder letters
Number of subjects: 739
Study 21781338 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (no reminders)
Number of subjects: 739
Study 18085514 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice and wine extract
Number of subjects: 0
Study 18085514 — intervention group
Group type: COMPARATOR
Intervention: Grape juice extract
Number of subjects: 0
Study 18085514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean section
Number of subjects: 0
Study 16606959 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 0
Study 16606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean section (first birth)
Number of subjects: 0
Study 16606959 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth (first birth)
Number of subjects: 0
Study 16606959 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean section (prior birth)
Number of subjects: 0
Study 16606959 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth (prior birth)
Number of subjects: 0
Study 12955409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 16 microg
Number of subjects: 36
Study 12955409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 24 microg
Number of subjects: 36
Study 12955409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 32 microg
Number of subjects: 36
Study 12955409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 40 microg
Number of subjects: 36
Study 12955409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine doses >16 microg
Number of subjects: 36
Study 11224966 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of moderate intensity exercise (brisk walking or equivalent) five days per week for six weeks
Number of subjects: 0
Study 11224966 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining existing levels of physical activity
Number of subjects: 0
Study 7747361 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrovesicography (EVG) in interstitial cystitis patients
Number of subjects: 9
Study 7747361 — intervention group
Group type: COMPARATOR
Intervention: Electrovesicography (EVG) in healthy women (control group)
Number of subjects: 9
Study 2402051 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 0
Study 2402051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol supplementation
Number of subjects: 0
Study 2402051 — intervention group
Group type: COMPARATOR
Intervention: Formula without supplements
Number of subjects: 0
Study 2402051 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 0
Study 7225481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (Li)
Number of subjects: 12
Study 7225481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30940201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamponade dressing after hemorrhoidectomy
Number of subjects: 953
Study 30940201 — intervention group
Group type: COMPARATOR
Intervention: No tamponade dressing after hemorrhoidectomy
Number of subjects: 953
Study 30940201 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesics use
Number of subjects: 953
Study 30940201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest hemoglobin documented within 7 days
Number of subjects: 953
Study 30940201 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and patient satisfaction
Number of subjects: 953
Study 30940201 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse and serious adverse events
Number of subjects: 953
Study 28335624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) - 16 sessions of 50 minutes each
Number of subjects: 344
Study 28335624 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram - 10-20 mg/day for 12 weeks
Number of subjects: 344
Study 28335624 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine - 30-60 mg/day for 12 weeks
Number of subjects: 344
Study 26250060 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin 500 mg plus metronidazole 400 mg (3x/day, 7 days)
Number of subjects: 406
Study 26250060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 23724548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini fiber‐reinforced composite (FRC) pins in Group C
Number of subjects: 30
Study 23724548 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal dentin pins in Group B
Number of subjects: 30
Study 23724548 — intervention group
Group type: COMPARATOR
Intervention: No pins (Group A)
Number of subjects: 30
Study 21707564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia using remifentanil (25-30 μg per bolus)
Number of subjects: 69
Study 21707564 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (50-75 mg)
Number of subjects: 69
Study 21707564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia using remifentanil
Number of subjects: 69
Study 21707564 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 69
Study 19621718 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day for 3 days before surgery (Group A)
Number of subjects: 31